These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 25317818)

  • 21. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
    Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
    Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.
    Ramelyte E; Dummer R; Guenova E
    Expert Opin Investig Drugs; 2019 Sep; 28(9):799-809. PubMed ID: 31398295
    [No Abstract]   [Full Text] [Related]  

  • 23. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
    Kim YH; Prince HM; Whittaker S; Horwitz SM; Duvic M; Bechter O; Sanches JA; Stadler R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown LC; Ortiz-Romero PL; Akilov OE; Trotman J; Taylor K; Weichenthal M; Walewski J; Fisher D; McNeeley M; Gru AA; Brown L; Palanca-Wessels MC; Lisano J; Onsum M; Bunn V; Little M; Trepicchio WL; Dummer R
    Eur J Cancer; 2021 May; 148():411-421. PubMed ID: 33794441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hematopoietic stem cell transplantation in advanced cutaneous T-cell lymphoma.
    Saruta H; Ohata C; Muto I; Imamura T; Oku E; Ohshima K; Nagafuji K; Nakama T
    J Dermatol; 2017 Sep; 44(9):1038-1042. PubMed ID: 28391645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
    Scarisbrick JJ
    Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
    Oh Y; Stoll JR; Moskowitz A; Pulitzer M; Horwitz S; Myskowski P; Noor SJ
    J Am Acad Dermatol; 2021 Nov; 85(5):1093-1106. PubMed ID: 33945836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hematopoietic Stem Cell Transplant for Mycosis Fungoides and Sézary Syndrome.
    Virmani P; Zain J; Rosen ST; Myskowski PL; Querfeld C
    Dermatol Clin; 2015 Oct; 33(4):807-18. PubMed ID: 26433851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome.
    Kawana Y; Suga H; Kamijo H; Miyagaki T; Sugaya M; Sato S
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD25+ folliculotropic Sézary syndrome with CD30+ large cell transformation.
    Jang MS; Kang DY; Han SH; Park JB; Kim ST; Suh KS
    Australas J Dermatol; 2014 Feb; 55(1):e4-8. PubMed ID: 23190349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States.
    Barta SK; Liu N; DerSarkissian M; Chang R; Ye M; Duh MS; Surinach A; Fanale M; Yu KS
    Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):e21-e32.e4. PubMed ID: 37919137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30 expression.
    Saintes C; Saint-Jean M; Renaut JJ; Dréno B; Quéreux G
    Br J Dermatol; 2015 Mar; 172(3):819-21. PubMed ID: 25113163
    [No Abstract]   [Full Text] [Related]  

  • 32. Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting.
    Reddy SA
    Crit Rev Oncol Hematol; 2016 Oct; 106():99-107. PubMed ID: 27637355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity.
    Papadavid E; Kapniari E; Pappa V; Nikolaou V; Iliakis T; Dalamaga M; Jonak C; Porkert S; Engelina S; Quaglino P; Ortiz-Romero PL; Vico C; Cozzio A; Dimitriou F; Guiron R; Guenova E; Hodak E; Bagot M; Scarisbrick J
    Br J Dermatol; 2021 Nov; 185(5):1035-1044. PubMed ID: 34137025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis.
    Vural S; Akay BN; Botsalı A; Atilla E; Parlak N; Okçu Heper A; Şanlı H
    Turk J Haematol; 2018 Mar; 35(1):35-41. PubMed ID: 28533196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
    Blackmon AL; Pinter-Brown L
    Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A case of refractory Sézary syndrome with large-cell transformation responsive to brentuximab vedotin.
    Corey K; Cook D; Bekker J; Mugnaini E; Lin JH
    JAMA Dermatol; 2014 Feb; 150(2):210-2. PubMed ID: 24352253
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of Alitretinoin for the Treatment of Mycosis Fungoides and Sézary Syndrome.
    Alhusayen R; Vu TT; Almuhanna N; Wohlmuth-Wieser I; Hardin J; Hughes JM; Chia J; Street L; Shear NH; Walsh SR; Gniadecki R
    Dermatology; 2021; 237(3):479-485. PubMed ID: 33429396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Management of mycosis fungoide : focus on brentuximab vedotin].
    Lebas E; Collins P; Bonnet C; Libon F; Dezfoulian B; Nikkels AF
    Rev Med Liege; 2021 Apr; 76(4):224-231. PubMed ID: 33830684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome.
    Lewis DJ; Haun PL; Samimi SS; Vittorio CC; Villasenor-Park J; Barta SK; Landsburg DJ; Svoboda J; Nasta SD; Schuster SJ; Rook AH; Kim EJ
    JAMA Dermatol; 2021 Mar; 157(3):317-321. PubMed ID: 33377934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.
    Lewis DJ; Rook AH
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):447-452. PubMed ID: 32320304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.